argenx NV ADR (ARGX)
$605.87 -$4.34 (-0.71%) 4:38 PM 12/11/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$37.26B -
Day's Range
$605.48 - $612.80 -
Volume
277,697 -
52 Week Low / High
$327.72 - $630.00 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 14
- Strong Buy
- 7
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong Sell
- $583.20
- Target Price
Company News
-
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...
-
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...
-
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...
-
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...
-
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...
-
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...
-
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024
Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...
-
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...
-
argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...
-
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...
-
Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024
For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...
-
argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024
For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...
-
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024
Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...
-
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024
Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024
For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024
For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...
-
Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024
For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...
-
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...
-
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024
Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...
-
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...
-
argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...
-
argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...
-
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024
Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...
-
argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...
-
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...
-
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024
Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...
-
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...
-
Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024
For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...
-
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...
-
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024
Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...
-
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024
Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...
-
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...
-
Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024
For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...
-
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024
As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...
-
Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024
For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...
Portfolio
Comprised of 1 portfolios